Cardiometabolic Risk

Cardiovascular, respiratory, and related conditions cause more than 40 percent of all deaths globally, and their substantial burden is rising, particularly in low- and middle-income countries (LMICs). Their burden extends well beyond health effects to include significant economic and societal consequences. Most of these conditions are related, share risk factors, and have common control measures at the clinical, population, and policy levels. Lives can be extended and improved when these diseases are prevented, detected, and managed. This volume summarizes current knowledge and presents evidence-based interventions that are effective, cost-effective, and scalable in LMICs.

This book discusses recent advances in the area of cardiometabolic risk biomarkers of chronic inflammatory and cardiovascular disorders. Tackling the topic in a systematic manner, the book starts with an introduction to cardiometabolic risk and its clinical relevance, comparing emergent and classical biomarkers. It then goes on to discuss cardiometabolic risk biomarkers in a range of diseases, including diabetes, ischemic stroke and neurodegenerative disorders. Biomarkers of Cardiometabolic Risk, Inflammation and Disease is aimed at doctors specializing in internal medicine, neurology, cardiology, rheumatology, nephrology or endocrinology and will also be of interest to GPs, trainee doctors and clinical and basic researchers working on cardiovascular and autoimmune disorders.

The first atlas devoted specifically to cardiometabolic risk, this book will provide a concise visual primer on the pathophysiology, epidemiology, diagnosis, treatment, and clinical and radiologic features of this disorder. Describing recent care strategies and current practices in patient assessment, this source will allow clinicians to accurately identify and treat those patients at increased risk for metabolic syndrome, cardiovascular disease, and diabetes.

This book analyzes in detail all aspects related to endocrine and metabolic late effects observed in patients treated for cancer, both in childhood and adulthood. The chapters focusing on the possible pathogenic mechanisms of late effects (i.e., premature aging and chronic inflammation) and on bone health in cancer survivors are particularly interesting and innovative. The volume also deals with hypothalamic-pituitary, thyroid and gonadal disorders, including infertility and how to prevent it. Finally, the relationship between metabolic alterations and cardiovascular diseases in cancer survivors is addressed. Thanks to advances in cancer treatment and supportive care, the five-year survival rate of cancer patients is constantly increasing. However, this undisputable success of medicine has a flip side: the late adverse effects of anticancer therapies. Pediatric oncologists were the first to cope with late complications of treatments, but today also adult oncologists and onco-hematologists recognize the relevance of this issue. Even though late effects observed in cancer survivors can affect any organ or system, endocrine and metabolic dysfunctions are the most frequently reported. Endocrine complications rarely influence life expectancy of cancer survivors, but they can significantly impact morbidity and quality of life. Among endocrine adverse effects, severe hypothalamic damage may be considered the most harmful in survivors, leading to morbid obesity, propensity to metabolic syndrome and cardiovascular disease. This book aims to disseminate the knowledge about endocrine and metabolic adverse effects of cancer therapies and about survivorship care. Since the number of cancer survivors is steadily growing in the general population, this publication is intended not only for endocrinologists but also for oncologists, onco-hematologists, internists, pediatric specialists in those areas and general practitioners, with the aim to better counsel and monitor cancer survivors.

A clinical guideline for the management of cardiometabolic diseases including diabetes, hypertension, dyslipidemia, obesity and smoking. It is a unique patient-centered guidelines for the primary health care providers, including physician, nurses and other health professionals. The book has a lot of implementation tools that may be downloaded online, as well. These include encounter forms, register diaries, quality indicators, clinical algorithms and many others. The book succeeded in gaining multiple awards and testimonials in medical conferences, internationally. It is a very comprehensive, stepwise approach, for the management of cardiovascular diseases, prevention and treatment.

The first atlas devoted specifically to cardiometabolic risk, this book will provide a concise visual primer on the pathophysiology, epidemiology, diagnosis, treatment, and clinical and radiologic features of this disorder. Describing recent care strategies and current practices in patient assessment, this source will allow clinicians to accurately identify and treat those patients at increased risk for metabolic syndrome, cardiovascular disease, and diabetes.

"In this compilation, the pathogenesis and interrelationships of metabolic abnormalities are discussed, particularly their impact on cardiovascular disease, as well as the role of excess adiposity in metabolic derange. The authors discuss the literature on polycystic ovary syndrome and cardio-metabolic risk factors, providing recommendations that would be helpful for healthcare providers and policy makers. Additionally, the aspects of nutritional habits associated to an increase in cardiovascular risk factors in the obese population are addressed"--